Previous studies have tested gene replacement therapy in RPE65-deficient dogs using recombinant adeno-associated virus 2/2 (rAAV2/2), -2/1 or -2/5 mediated delivery of the RPE65 gene. They all documented restoration of dark-and light-adapted electroretinography responses and improved psychophysical outcomes. Use of a specific RPE65 promoter and a rAAV vector that targets transgene expression specifically to the RPE may, however, provide a safer setting for the long-term therapeutic expression of RPE65. Subretinal injection of rAAV2 pseudotyped with serotype 4 (rAAV2/4) specifically targets the RPE. The purpose of our study was to evaluate a rAAV2/4 vector carrying a human RPE65cDNA driven by a human RPE65 promoter, for the ability to restore vision in RPE65 À/À purebred Briard dogs and to assess the safety of gene transfer with respect to retinal morphology and function. rAAV2/4 and rAAV2/2 vectors containing similar human RPE65 promoter and cDNA cassettes were generated and administered subretinally in eight affected dogs, ages 8-30 months (n ¼ 6 with rAAV2/4, n ¼ 2 with rAAV2/2). Although fluorescein angiography and optical coherence tomography examinations displayed retinal abnormalities in treated retinas, electrophysiological analysis demonstrated that restoration of rod and cone photoreceptor function started as soon as 15 days post-injection, reaching maximal function at 3 months postinjection, and remaining stable thereafter in all animals treated at 8-11 months of age. As assessed by the ability of these animals to avoid obstacles in both dim and normal light, functional vision was restored in the treated eye, whereas the untreated contralateral eye served as an internal control. The dog treated at a later age (30 months) did not recover retinal function or vision, suggesting that there might be a therapeutic window for the successful treatment of RPE65 À/À dogs by gene replacement therapy.
Introduction
Inherited retinal dystrophies are a heterogeneous group of disorders that nearly always share one critical feature, degeneration of photoreceptors. Retinal dystrophies often lead to blindness and currently there are no effective treatments. The most common retinal dystrophy is retinitis pigmentosa (RP), affecting approximately 20 000 individuals in France. 1 Onset of RP is characterized by a severe night blindness, followed by a progressive constriction of the peripheral visual fields, and finally by central vision impairment, resulting in total blindness.
Leber congenital amaurosis (LCA) is a specific type of retinal dystrophy, more severe than RP and responsible for infantile blindness. This congenital blindness has a worldwide prevalence of three in 100 000 newborns and affects 1000-2000 children in France. LCA was first described in 1869 by a German ophthalmologist, Theodor Leber. His original description is still used today and includes the following features: severe visual loss at or near birth, wandering nystagmus, amaurotic pupils and a pigmentary retinopathy. Non-detectable or a severely reduced electroretinogram is also recognized as an important diagnostic feature. 2 There are now eight genes identified, whose mutations cause LCA. 3, 4 These genes are all expressed preferentially in the photoreceptor cells or in the retinal pigment epithelium (RPE). In photoreceptors, these genes encode enzymes of the phototransduction cascade, photoreceptor-specific structural proteins or transcription factors. In the RPE, LCAassociated genes encode proteins involved in vitamin A (all-trans retinol) metabolism and recycling of retinoids between photoreceptors and RPE (visual cycle). A recent study reported a comprehensive mutational analysis of all the known genes in 179 unrelated patients. Accounting for most cases was GUCY2D (21.2%), followed by CRB1 (10%), RPE65 (6.1%), RPGRIP1 (4.5%), AIPL1 (3.4%), TULP1 (1.7%) and CRX (0.6%). 3 Extrapolating from this report, one can then estimate that 100-200 LCA patients in France are carrying a mutation in the RPE65 gene. Currently, there are no effective treatments for these disorders and gene therapy offers an attractive approach to treatment. Recombinant adeno-associated virus 2 (rAAV2) vectors are among the most efficient gene delivery vehicles for treatment of retinal diseases, as the tropisms and transduction patterns of these vectors lead to efficient and stable gene transfer in RPE, photoreceptor and/or ganglion cells. 5 Since the discovery of AAV2, over 100 AAV isolates have been described and more than 10 cloned for development as gene therapy vectors. 6, 7 RPE65 is an abundant protein in the RPE and is associated with the microsomal membrane. 8, 9 It plays an essential role in vitamin A metabolism and is necessary for the synthesis of the visual pigment chromophore 11-cis retinal. 10 Two recent studies have identified RPE65 as the isomerase that efficiently generates 11-cis retinol from all-trans retinyl ester. 11, 12 A number of mutations in the RPE65 gene are associated with inherited retinal dystrophies in humans [13] [14] [15] and in dogs. 16, 17 The fact that there are close similarities between humans and dogs, in terms of the clinical characteristics of disease resulting from RPE65 gene mutations, make the RPE65 À/À Briard a valuable model for the evaluation of gene replacement therapy. Two groups have now reported restoration of vision in beagle-Briard RPE65 À/À dogs [18] [19] [20] [21] using rAAV2/2-, rAAV2/1-or rAAV2/5-mediated delivery of an RPE65 gene.
The use of the native human RPE65 promoter and an rAAV vector that targets transgene expression specifically to the RPE might provide a safer approach for the long-term therapeutic expression of RPE65. We have previously demonstrated that, in contrast to rAAV2/2, rAAV2/4 allowed exclusive transduction of RPE in the rat, dog and primate. 22 The present study was designed to evaluate the efficacy of rAAV2/4-mediated gene therapy to restore vision in RPE65 À/À purebred Briard dogs and to assess the safety of gene transfer with respect to retinal morphology and function.
Results
Subretinal injection of AAV2/4.hrpe65 and AAV2/2.hrpe65 in RPE65 À/À Briard dogs
We have produced an AAV2 backbone containing a human RPE65cDNA gene driven by a human RPE65 promoter. The RPE65cDNA was placed under the control of a 1.6 kb fragment of its natural promoter in order to minimize ectopic expression of the transgene. The AAV2 backbone containing the therapeutic construct (hrpe65) was packaged as either rAAV2/2 or rAAV2/4. A total of nine affected purebred Briards (A1-A9) were injected subretinally within the tapetal retina. The first six affected Briards (A1-A6) were treated with AAV2/4.hrpe65, whereas A7, A8 were injected with AAV2/2.hrpe65 (Table 1 ). An affected Briard (A9) was injected with vehicle alone, to serve as a negative control. In all animals, only one eye was treated, with the contralateral eye serving as an internal control for ophthalmic examination and vision testing. Based on our previous experience with subretinal injection in dogs and primates, 22, 23 our initial aim was to inject 400-500 ml of vector suspension into each treated retina. We observed that in contrast to normal retinas, the retinal detachment, or bleb, created during subretinal injections in RPE65 À/À dogs was not reproducible in all animals, and was likely due to individual variation in retinal adhesion. The amount of vector injected therefore varied from 150 to 500 ml.
Evaluation of retinal morphology after subretinal injection in Briard dogs
In order to monitor retinal morphology and eventual chorioretinal alterations owing to rAAV2/4-or rAAV2/ 2-mediated gene transfer, all dogs received ophthalmic examination including funduscopy, fluorescein angiography and optical coherence tomography (OCT). The fundus of the most pigmented eyes displayed hyperpigmentation that delineates the border of the bleb area (Figure 1a and e) . Surprisingly, the angiograms of all the subretinally injected affected Briards, except A2, displayed hyperfluorescent zones within the portion of the retina that was detached during the injection of the rAAV vector or vehicle (Figure 1a-e) . These hyperfluorescent areas were detected as soon as 2 weeks post-injection (during the first Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al angiography performed after the surgery) but did not expand overtime (up to 12 months post-injection). When compared with the fundus photographs, the hyperfluorescent areas detected on angiograms corresponded to the brighter areas observed in the fundus (Figure 1c and e). These abnormalities suggest that subretinal injections cause localized trauma leading to retinal thinning and cell destruction in that part of the retina which was detached during injection in RPE65 À/À dogs. Interestingly, these abnormalities have never been observed in normal beagle dogs, treated with either the AAV2/4.hrpe65 or with AAV2/2.hrpe65 vector (data not shown), or in nonaffected Briard dogs treated with vehicle alone (Figure 1f) .
OCT is a non-contact, non-invasive optical imaging technique that measures the intensity of backscattered light. 24, 25 OCT produces cross-sectional images of optical reflectivity in the tissue, analogous to B-scan ultrasonography, thus providing greater resolution by using light instead of sound waves. OCT imaging was performed in all treated animals in order to monitor the success of the subretinal injection and subsequent recovery from the initial subretinal bleb. OCT imaging at 15 min post-injection documented that the vector preparation was successfully injected in the subretinal 
Kinetics of retinal function recovery in treated Briard dogs
Retinal function was tested using simultaneous bilateral full-field flash electroretinography (ERG) before surgery and, in order to assess the kinetics of recovery of function, at different time-points post-injection. The same investigator (GL) recorded the ERGs in a standardized manner. Follow-up with ERG was 12 months postinjection for A1 and A2, 9 months for A3, A4, A5, A7 and A8, and 5 months for A6. The ERG profiles of A1 and A5 overtime are presented in Figure 3 . The kinetics of recovery of function in all treated affected Briards are Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al presented in Figure 4 . All affected Briards treated with AAV2/4.hrpe65 or AAV2/2.hrpe65 vector between the age of 8 and 11 months (A1-A5 and A7-A8, respectively) displayed rod and cone function recovery in the treated retina in contrast to A6 which was injected with AAV2/ 4.hrpe65 at the age of 30 months and to A9 which received the vehicle alone (Table 1 , Figures 3 and 4) . For the seven animals that displayed ERG improvements, restoration of rod and cone photoreceptor function started as soon as 15 days post-injection, was maximal at 3-4 months post-injection, and remained stable thereafter in all treated retinas. The cone-ERG response improved dramatically between 15 days and 2 months post-injection and increased slowly thereafter. The rod-ERG response gradually increased between 45 days and 3 months post-injection and remained stable thereafter. For example, in A1, the maximum recovered amplitude of the dark-adapted b-wave was 78% of unaffected RPE65 +/À dogs. The maximum recovered amplitude of the 30 Hz flicker amplitude is 70% of RPE65 +/À unaffected dogs. Although the general trend of ERG recovery is similar in all Briard dogs treated between the age of 8 and 11 months, individual variations were observed. In A2, for example, a dramatic improvement of the ERG response occurred later than in other animals and was observed between 3 and 4 months post-injection (ERG max. varied from 44 to 71 mV). This might be due to the smaller volume of AAV2/4.hrpe65 vector injected in A2 (150 ml) compared with A1, A3, A4 and A5 (220-400 ml). In spite of the larger volume of vector injected into the two AAV2/2.hrpe65-treated dogs (330 and 500 ml for A7 and A8, respectively), the onset of function recovery was slower than in AAV2/4.hrpe65 dogs (Figure 4) . In a majority of the seven affected dogs with ERG improvements, the ERG max. levels obtained were correlated with the amount of AAV2/4.hrpe65 or AAV2/2.hrpe65 injected. A4 and A5, which received 300 and 400 ml of vector, respectively, showed better recovery than did A2 and A3, which received 150 and 280 ml, respectively, of the same vector suspension. Similarly, between the AAV2/2.hrpe65-treated dogs, A8 (500 ml) displayed higher ERG max. than A7 (300 ml).
The full-field ERG reflects electrical activity summed across the entire retina and provides no information about local retinal activity. The development of the multifocal ERG (MF-ERG) technique allows to gain information about localized retinal function. MF-ERG has been demonstrated to be very useful in the detection of topographical distribution of disease in many inherited retinal degenerations. 26 The treated affected dog A1 was examined at 12 months post-injection with the RETIscan MF-ERG system using 61 equal sizing hexagonal elements within a visual field of approximately 321 radius. Trace arrays of recordings obtained in the untreated and treated eyes are presented in Figure 5 . In the untreated right retina (Figure 5a ), baseline or very low levels of MF-ERG amplitudes were detected across the stimulated area (ampl.b 0.4-5.2 nV/degree 2 ). In the treated left retina (Figure 5b ), high levels of amplitudes were found in the transduced area of the retina. Interestingly, a gradient in the MF-ERG amplitudes was observed between areas corresponding to the middle of the bleb (ampl.b 21.5 nV/degree 2 ) and the edge of the bleb (12.5 nV/degree 2 ). It is important to note that the maximum MF-ERG amplitude detected in the treated retina of A1 is lower (60%) than the one found in the unaffected dog (48.2 nV/degree 2 ) (Figure 5b and c) .
Restoration of vision
We evaluated vision in all nine treated Briards using behavioral testing at different time-points post-injection. This evaluation started at 150 days post-injection (d.p.i.) for A1 and A2, 60 d.p.i. for A3-A5 and 45 d.p.i. for A6-A9 (Table 2 ). Visual assessment was based on the ability to avoid obstacles in both dim and normal light. The obstacle course was arranged such that the Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al placement of obstacles was unique from trial to trial. Given that residual vision might have varied between affected individuals, we used the untreated contralateral eye as an internal control. All treated dogs, except A6, consistently avoided obstacles when the untreated eye was covered with an opaque contact lens and the treated eye was left uncovered. However, when the opaque contact lens was placed on the injected eye and the untreated eye was left uncovered, dogs consistently failed to avoid obstacles (Supplementary video 1) . It was 60dpi  45dpi  30dpi  15dpi  bi  60dpi  45dpi  30dpi  15dpi  i  p  d  0  9  bi  120dpi  120dpi  90dpi  150dpi  150dpi  180dpi 180dpi 270dpi 270dpi Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al interesting to observe that restoration of vision was stable up to 12 months post-injection for A1 and A2 (duration of the experiment). A6 consistently failed to avoid obstacles.
Expression of RPE65 in treated eyes: immunocytochemistry and histopathology
All the treated dogs that responded to treatment were kept for long-term study. A6 was killed at 6 months postinjection for histological assessment of the retina. The right treated eye was used for immunocytochemical studies, whereas the uninjected contralateral eye was used for histopathological examination (Figure 6 ). The eye receiving the AAV2/4.hrpe65 vector showed very distinct RPE65 labeling in the RPE cells of the treated area (Figure 6b) . No other cells showed RPE65 protein expression; in particular, the photoreceptors remained RPE65 negative. The non-treated area of the retina did not display any RPE65 immunolabeling (Figure 6c) . Although there were no appreciable differences in the thickness of the nuclear layers in comparison with equivalent regions of the retina from a normal dog (Figure 6d and e) , the structure of the photoreceptor outer segments did not appear normal in A6 (Figure 6e) .
In order to better evaluate the retinal alterations observed on the fluorescein angiograms and the OCT Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al images, A9, the mock-injected RPE65 À/À dog, was killed at 12 months post-injection and the injected eye was used for histopathology. Two types of lesions were observed. At the injection site that appears as a 'black spot' on the fluorescein angiogram (Figure 1e) , accumulation of debris and macrophages is detected in the subretinal space (Figure 6f ). In the transduced part of the retina showing hyperfluorescence on the fluorescein angiogram (Figure 1e) , loss of RPE and photoreceptors outer segments was observed with disorganization of the inner and the outer nuclear layer (Figure 6g ).
Discussion
In this study, we have demonstrated that a single subretinal injection of an rAAV2/4 vector containing a Rhodopsin staining (green) in the rod outer segments remains unchanged in all three retinas. RPE, retinal pigment epithelium; OS, outer segments; IS, inner segments; ONL, outer nuclear layer. As observed on paraffin section, there were no appreciable differences in the thickness of the nuclear layers of comparable regions of the retina of a normal dog (d) with the untreated contralateral retina of A6 (e). Histological sections of the subretinally injected eye of A9 (vehicle only) illustrate the two types of lesions caused by the subretinal injection, one is located at the injection point (f) and the other correspond to the part of the retina that was hyperfluorescent on the fluorescein angiogram (g).
Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al human-specific RPE65 promoter and cDNA, into five RPE65 À/À purebreed Briard dogs aged between 8 and 11 months, restores retinal function and vision. Moreover, rescue of rod and cone function in these animals was as efficient, if not more efficient, than in dogs treated with an rAAV2/2 vector carrying the same therapeutic cassette. The dog treated at the age of 30 months, using the same batch of AAV2/4.hrpe65 vector, did not show any ERG or visual improvements despite expression of the therapeutic transgene.
The volume of vector suspension delivered in affected dogs varies from 150 to 500 ml. We found that retinal adhesion differs between individual RPE65-deficient animals and this affected the size of the retinal detachment created during the subretinal injection. This variation, which has not been observed in the retina of normal dogs or primates, 22, 23, 27 is likely to be associated with RPE65
À/À disease status. This type of complication may also occur in RPE65-deficient LCA patients and should be taken into account when designing gene therapy protocols. In contrast with the previous study by Narfstrom et al., 20 we have never observed perioperative complications such as ocular inflammation or uveitis.
Fluorescein angiograms of the treated retina of all affected dogs, except A2, displayed areas of hyperfluorescence within those parts of the retina that were detached during the subretinal injection. The fact that normal beagle dogs, injected with the same rAAV2/4 or rAAV2/2 vector suspension, did not have this abnormality suggests that this phenomenon is not due to the vector itself. Moreover, A9, which was injected with vehicle only, also had similar hyperfluorescent spots as early as few days post-injection. For all injected eyes, the hyperfluorescent areas observed on the fluorescein angiograms did not expand overtime. As observed by OCT, some areas of the retina that are hyperfluorescent on the fluorescein angiograms displayed a reduction in normal retinal thickness, suggesting cell destruction. All together, these observations suggest that the abnormal retinal morphology found in treated affected Briard dogs is related to the retinal detachment created during subretinal injection of an RPE65 À/À affected retina. Similar structural alterations specific to subretinal injection of affected dogs has been previously described in one RPE65
À/À dog. 21 The fact that angiograms and OCT are normal in A2 may be due to the small size of the bleb (only 150 ml was injected) and therefore the small area of retinal detachment. In previous studies involving subretinal injection of rAAV vectors in normal dogs and macaques, such abnormalities were never observed. 22, 23, 27 Fortunately, the detected retinal abnormalities seen in all animals treated under a year of age did not prevent rescue of retinal function. All the treated dogs, except A6 that was treated at a much older age, showed retinal and visual functions. For most of the animals that displayed ERG improvements, restoration of rod and cone photoreceptor function started as soon as 15 days postinjection. Direct comparison between rAAV2/4-and rAAV2/2-treated animals suggested that rAAV2/4 displayed faster onset in restoration of retinal function. Although both vectors were of the same titer (10 11 vector genomes/ml (vg/ml)), one cannot exclude that the ratio between total particles and transducing units was different, especially as the vectors were produced by different facilities. rAAV2/4 was produced by the vector core facility in Nantes and the rAAV2/2 was produced by Targeted Genetics (Seattle, WA, USA).
The striking behavioral improvements seen in the treated individuals was due entirely to functional restoration in the treated eye, as dogs consistently failed to avoid obstacles when the treated eye was covered. This also demonstrated that rAAV treatment in one eye does not lead to improved visual function in the contralateral eye in the dog model. The same observation was made in the rd12 mice, carrying a recessive nonsense RPE65 mutation, treated with a AAV5-CBA-hrpe65 vector. 28 Although recombinant RPE65 protein was expressed in the transduced retina of A6 (as observed by immunocytochemistry), no rescue of function or vision was observed in this affected Briard following treatment at the age of 30 months. In RPE65 À/À patients or dogs, reduced vision is consistent with two possible disease mechanisms or a combination thereof: (i) an interrupted retinoid cycle that is potentially treatable by RPE65 gene replacement, and (ii) death and loss of photoreceptors. It is not clear why defects in RPE65 produce cell death. In RPE65 À/À mice, it has been reported that it is the activation of phototransduction by unliganded opsin, and not the accumulation of retinyl ester, which causes light-independent retinal degeneration in LCA. 29 Thinning of the retina was not observed in A6, suggesting that the photoreceptors were still alive but with abnormal outer segments. It is possible that at 30 months of age, in this dog, dysfunction of RPE or photoreceptors prevented rescue of vision. Additional studies on a larger cohort of older RPE65 À/À dogs will be required to elucidate this question.
In conclusion, we have demonstrated that targeted gene transfer to the RPE followed by cell-specific transgene expression using a rAAV2/4 vector, can be used to correct the RPE65 defect in RPE65 À/À purebred Briard dogs, leading to the stable restoration of normal retinal function and vision-dependent behavior. The main potential advantage for the use of an rAAV2/4 vector that targets transgene expression specifically to the RPE is to provide a safer approach to treat LCA patients. Although the problem of retinal alterations linked to the subretinal injection in RPE65 À/À retina does not prevent the rescue of vision, it is important to be aware of this potential complication when designing gene therapy protocols. Subretinal injection of the therapeutic vector will have to be performed outside the fovea. Finally, the relative contributions of dysfunction or cell death to the extreme visual loss in human RPE65 deficiency are unknown. However, analysis of our results in dogs suggests that for successful gene therapy to occur in humans, patients should be treated at a relatively young age.
Materials and methods

AAV-2/4.hrpe65 vector
Construct pD10-hRPE65P-hRPE65, used for the production of both AAV2/4-hrpe65 and AAV2/2-hrpe65, consists of the coding sequence of the human RPE65cDNA between a fragment of the human RPE65 promoter (bp À1556 to +23 relative to the transcription start site) and an simian virus 40 polyadenylation site. This expression Vision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al cassette was cloned replacing the CMV-GFP cassette of construct AAV-CMV-GFP, 30 which contains the ITRs of AAV2. The AAV2/4.hrpe65 vector was produced as previously described by Rabinowitz et al. 31 in the Vector Core at the University Hospital of Nantes (http:// www.vectors.nantes.inserm.fr). The AAV2/2.hrpe65 vector (provided by Targeted Genetics Corporation, Seattle, WA, USA) was produced using the B50 AAV2 packaging cell line and an Ad/AAV hybrid containing the same rAAV construct that was used to make the AAV2/4.hrpe65 vector. 32 For both rAAV vectors, the titer was determined by dot blot and is expressed as vg/ml. 33 The titers were 10 12 and 10 11 vg/ml for rAAV-2/2 and rAAV-2/4, respectively. The rAAV2/2 was diluted in order to generate 10 11 vg/ml aliquots.
Subretinal injection
A colony of Briard dogs carrying the RPE65 null mutation was developed at the Boisbonne Center (Veterinary School of Nantes). All animals were cared for in accordance with the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research. The subretinal injections were performed via a transvitreal approach, following vitrectomy. Procedures were conducted on dogs under isofluorane gas anesthesia as previously described by Weber et al. 22 The protocol was approved by the Institutional Animal Care and Use Committee of the University of Nantes.
Fluorescein angiography
Pupils of the animals were dilated 20 min before anesthesia using tropicamide (Ciba Vision Faure, Novartis, Annonay, France) and phenylephrine hydrochloride (10% Neosynephrine, Novartis). Animals were anesthetized with an intravenous injection of ketamine (Imalgène, Rhone Merieux, France) and medetomidin (Domitor, Pfizer, Paris, France). Fluorescein angiography were imaged using a Canon UVI retinal camera connected to a digital imaging system (Lhedioph Win Software, Lheritier SA, Saint-Ouen-l'Aumô ne, France). Sodium fluorescein solution (fluorescein sodique Faure 10%, Ciba Vision Ophtalmics, 0.1 mg/Kg) was injected intravenously. The photograph sequence, using barrier filters, was begun after injection with the fluorescein exciter and continued until the dye was eliminated from circulation.
Optical coherence tomography
Retinal morphology was assessed by OCT (Stratus 3000, Zeiss, Oberkochen, Germany). Dilatation of the pupils and intravenous anesthesia of the animals were performed as described above. Examination was performed at different time-points post-injection, by doing a 3 mm scan in the area of the bleb in the injected eye and the corresponding area of the contralateral, non-injected eye.
Electroretinography
Global retinal function was tested using simultaneous bilateral flash photopic and scotopic ERG. ERGs were recorded in a standardized manner, according to the International Society for Clinical Electrophysiology of Vision (ISCEV) protocols, 34 using a computer-based system (Neuropack m MEB-9102K, Nikon-Kohden, Tokyo, Japan) and contact lens electrodes (ERGjet, Microponent, Le Cret-du-Locie, Switzerland). Bandpass filter cutoff frequencies were 1 and 100 Hz for all measurements. Analysis time was 100 ms. The a-wave amplitude was measured from the baseline to the a-wave peak and the b-wave amplitude was measured from the a-wave peak to the b-wave peak, whereas flicker amplitude was measured peak to peak. The uninjected eye served as a within animal control.
MF-ERG
MF-ERG responses of A1 were obtained with the RETIscan system (Roland Consult, Wiesbaden, Germany), using 61 equal sizing hexagonal elements within a visual field of approximately 321 radius. The stimulus was presented on a 21-inch monitor viewed at 24 cm distance within a central 641 total visual field (visual angle of 321). Each hexagon element changed in time between black and white (contrast was approximately 98%) following a binary m-sequence. Each hexagon was modulated at the frequency of 60 Hz with an on/offprobability of 0.5. The traces produced by the computational procedure were twice smoothed by an algorithm within the software (RETIscan version 3.15).
Data acquisition consisted of eight sessions of 47 s each. The signals were band pass-filtered with a high cutoff at 100 Hz and a low cutoff at 1 Hz. By cross-correlation analysis between stimulation patterns and their responses, 61 focal mfPERGs can be displayed, and shown in the figures in their relative topographical positions. The position of the treated area of the A1 retina was evaluated using a binocular indirect ophthalmoscope.
Behavioral studies
We recorded ambulation of treated and untreated RPE65 À/À dogs through an obstacle course in both dim and normal light using a camcorder. An opaque lens, specifically designed for dogs, was used to alternatively cover the treated or the untreated eye. The number of collisions through the obstacle course was compared between the course for which the untreated eye was covered and the course in which the treated eye was covered.
Histopathology and immunocytochemistry
Eyecups were obtained from normal and affected dogs and were either processed by a 4% paraformaldehyde fixation, for embedding in inclusion compound (Sakara Finetek, Torrance, CA, USA) and immunocytochemistry, or fixed for 48 h in Bouin's solution, followed by paraffin embedding for histopathological examination. For immunocytochemical studies, 10 mm sections of OCT embedded retinas were thawed and rehydrated with phosphate-buffered saline (PBS) (pH 7.4). The sections were blocked with 5% bovine serum albumin in 0.1% PBS/Tween for 20 min at room temperature, and incubated overnight at 41C with the following primary antibodies in blocking solution: mouse monoclonal antiRho-4D2 antibody (1:100; kindly provided by Dr Molday, Vancouver, Canada) and rabbit polyclonal anti-RPE65 antibody (1:200; this antibody was raised against the fulllength recombinant RPE65 protein, and purified on a protein A column). After washing with PBS, sections were incubated with fluorescein isothiocyanate-conjuVision restoration in RPE65-deficient Briard dogs using AAV serotype 4 G Le Meur et al gated donkey anti-mouse (1:400) and tetramethyl rhodamine isothiocynate-conjugated donkey anti-rabbit (1:200) secondary antibodies (Jackson ImmunoResearch Laboratories Inc., Europe Ltd, Newmarket, UK) diluted in blocking solution for 2 h at room temperature. After washing with PBS, nuclei of photoreceptors were stained by incubation with TOPRO-3 (1:1000; Molecular Probes Inc., Invitrogen, Cergy Pontoise, France) in blocking solution for 30 min at room temperature. Sections were mounted with antifade medium (ProLong Antifade Kit, Molecular Probes Inc.) and examined by epifluorescence microscopy (Nikon, Champigny-sur-Marne, France). For histopathological examinations, paraffin-embedded sections were stained using a standard hematoxylin-eosinsaffranin staining protocol and viewed with bright-light microscopy and differential interference contrast optics (Nikon, France).
